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The COVID-19 pandemic has brought out the best of
the health and social care workforce globally, as
acknowledged by the public. But the clapping has
now stopped. Over 50,000 people who tested positive
for coronavirus in the UK have died, a tragic figure
that is more than double the UK Government’s early
‘best case scenario’ estimate. Each death represents a
life lost too soon, leaving behind grieving family and
friends. At the same time, doctors and other health-
care professionals are exhausted and anxious, fearing
both the implications of a second wave, and possible
repercussions from decisions made under the strain of
the pandemic.
There has been polarised debate around whether
doctors should be granted immunity from civil and
criminal negligence claims and regulatory proceed-
ings arising from treatment provided during
COVID-19.1,2 Here, we argue that this focus on tem-
porary statutory immunity is a distraction from pre-
existing concerns that several aspects of the current
medicolegal system are not fit for purpose – for doc-
tors or for patients. Areas where there is no ‘quick fix’
include: the need for reform of the clinical negligence
system; concerns in relation to regulatory proceed-
ings; and the potential for BAME (black, Asian,
and minority ethnic) doctors (and patients) to be dis-
proportionately impacted in both areas. These issues
are critical, since they each have a direct impact on
multiple stakeholders, including on those who deliver
and receive healthcare. However, there has been a
tendency for these to be considered from single-
minded viewpoints; accordingly, we aim in this
paper to provide a more holistic view. Rather than
pursuing immunity legislation, we say that the time is
right for more comprehensive action, including an
independent Public Inquiry to scrutinise these
issues, taking into account all of the interests engaged
(Figure 1).
Moving beyond immunity: the case for
medical negligence reform
It bears repetition that patient safety issues are
notoriously under-reported and, in most cases
where a patient has suffered harm following a medical
error, a claim in negligence is not pursued. In the
minority of cases, doctors (and indeed other health-
care professionals) may find themselves exposed to
liability for negligent medical treatment, but only
when they have provided diagnoses or treatment
that fall below the standard of a reasonable doctor,
and where this has caused harm. This can be dealt
with under criminal and/or civil law. While criminal
cases are extremely rare, a recent review of gross neg-
ligence manslaughter, led by Sir Norman Williams,
acknowledges both the effects of the unexpected
death of a loved one for bereaved family and friends,
and also the effect this may have on the medical team
providing care.3 Recommendations from this review
underpin the need for a just and learning culture in
healthcare, where cases can be dealt with fairly, trans-
parently and compassionately. It further highlights
the disproportionate representation of BAME profes-
sionals within criminal proceedings, and calls for
careful consideration to avoid perceived (and, by
implication, actual) injustice.
Contrast this with recent discussions in the UK
concerning whether doctors should be granted
immunity from proceedings in respect of treatment
provided during the COVID-19 pandemic, along the
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lines of emergency legislation introduced in some US
states, including New York.2 This US legislation grants
healthcare professionals, acting in good faith, tempor-
ary immunity from civil and criminal liability (but not
wilful or intentional criminal harm, or reckless miscon-
duct). However, it does not extend to protection
against regulatory proceedings.4 The debate in the
UK has focused in particular on immunity from clin-
ical negligence claims.1 Those in favour point to the
emotional and professional burden of dealing with a
clinical negligence claim, regardless of the outcome,
and even if doctors are protected financially by state-
backed indemnity arrangements. Those to the contrary
contend that immunity is superfluous and inappropri-
ate, given the ability of the law as it stands to protect
doctors from being unfairly judged, the extraordinary
circumstances in which treatment has been provided
and the need to consider, among other interests,
those of patients. Both sides of the debate raise import-
ant points, but we suggest that, by narrowing the dis-
cussion to COVID-19-specific short-term statutory
measures, this obscures three more pressing and per-
sistent issues in the medicolegal landscape, the first of
which is the unsatisfactory state of the clinical negli-
gence system.
The need for clinical negligence reform has been
mooted for over 30 years. COVID-19 is not the
genesis of these issues; rather it has brought into
sharp relief longstanding problems with the system.
Concerns beyond the pandemic relate to the financial
cost of clinical negligence claims, and the resulting
impact on the availability of resources for healthcare,
not only in monetary terms, but also in relation to the
clinical and administrative burden this generates.5 A
recent review of medical device safety also highlights
the negative impact of current processes for redress
following medical harm on patients, including finan-
cial hardship, family breakdowns, and loss of identity
and self-worth.6 Administrative schemes that are lim-
ited to low-value claims, and directed more to cost
control than addressing patient concerns, have thus
far failed to deliver a ‘just redress scheme’,7 or a com-
prehensive alternative to the status quo. Real change
will not come about through the ‘quick fix’ of tem-
porary immunity, but rather through sustained, sys-
tems-level action to support staff, improve patient
safety, and commitment to a just and learning culture
in healthcare,5 as endorsed in the criminal context by
the Williams review.3
NHS Resolution has recently highlighted a
number of concrete examples of how this can be
achieved in their 2019 report, Being Fair.8 In particu-
lar, this underlines the benefits of a restorative
approach in the aftermath of incidents, which
Figure 1. The medicolegal landscape through the lens of COVID-19. Reform needed in clinical negligence and regulatory
spheres and an assessment of the medicolegal impact on BAME doctors and patients.
BAME: black, Asian, and minority ethnic.
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‘holds people accountable by looking forward to
what must be done to repair, to heal and to prevent’.9
This practice is not merely aspirational; it has been
operationalised by Mersey Care, an NHS
Foundation Trust providing mental health services,
to deliver a transformative shift from a culture of
blame to one of trust and learning. This initiative,
and others, which stem from a collaborative
approach, underline the interconnectedness of patient
safety and staff wellbeing, and the need to engage
with multiple perspectives to drive real change.
Regulatory proceedings
Our second concern is that an exclusive focus on
immunity legislation also narrows consideration of
medicolegal issues to civil claims for medical negli-
gence, when, in fact, many doctors are more worried
about the prospect of a complaint to the General
Medical Council in relation to their fitness to prac-
tise. This is outwith the scope of the US immunity
legislation referred to above. In the UK, this is a
particularly thorny issue in the medical community,
given pre-existing unease concerning the individual-
isation of systemic failures, in particular following the
criminal and regulatory proceedings pursued against
Mr David Sellu and Dr Hadiza Bawa-Garba, among
others.
During the pandemic, the position has remained
that the General Medical Council’s professional guid-
ance applies. However, healthcare professionals’
anxieties have not gone unheeded; the chief execu-
tives of the health and social care regulators issued
an early joint statement on how they will regulate in
light of COVID-19.10 Many have welcomed recogni-
tion from their regulatory body of the challenging
circumstances in which they are operating, and of
the flexibility that the pandemic response has
demanded, including working in unfamiliar sur-
roundings or being redeployed to different clinical
areas.11
So where does this leave doctors who are con-
cerned about fitness to practise proceedings?
Guidance from the British Medical Association indi-
cates that complaints are unlikely when decisions are
reasonable, based on the best available evidence,
informed by guidance, collaborative and, as far as
possible, promote effective and safe care.12 We fur-
ther welcome the joined-up approach of the regula-
tors which, in our view, points to an
acknowledgement that the pandemic response is a
‘team effort’. As noted in the General Medical
Council’s own guidance about prioritising access to
treatment, difficult decisions should not, as far as is
practicable, fall on one clinician’s shoulders. Most
recently, the General Medical Council has issued spe-
cific guidance on how it will assess the risk to public
protection posed by a doctor as a result of concerns
about their practice during the pandemic.13 This will
sit alongside existing guidance and processes in order
to inform the work of General Medical Council staff
who look into fitness to practise concerns on a case-
by-case basis.
But what other steps could be taken as we move
forward, and as memories of recent working condi-
tions dull? The exclusion of regulatory action from
the emergency immunity legislation enacted in some
US states was unlikely to have been an oversight. To
preclude patients from making any complaint in rela-
tion to the pandemic to a body charged with their
protection is a draconian measure and, in the UK,
incompatible with the General Medical Council’s
statutory objective and functions. The role of
ongoing and responsive engagement by the General
Medical Council – with doctors, patients and other
stakeholders – is vital to maintain the public’s and
professionals’ trust in the regulatory system.
Organisational memory is a key part of creating a
just culture in healthcare, which, in turn, has been
shown to improve patient safety. As such, we do
not characterise this task as a ‘balance’ to be struck
between supporting doctors, on the one hand, and
protecting patients on the other, with the implication
that promoting one interest necessarily diminishes the
other. The porosity of these roles has been laid bare
by the pandemic, where caregivers have become
patients, and members of the public have stepped
up to support the delivery of NHS services. Here,
too, we would also urge consideration of the bigger
picture; it is more essential than ever that the regula-
tory system itself is fit for purpose. Over six years ago,
the Law Commission’s report outlined sweeping legis-
lative changes to the regulation of health and social
care professionals in the UK, to fix a legislative frame-
work that is ‘cumbersome and inflexible’.14 The
Government’s response promised to make changes
that will facilitate more efficient and responsive fitness
to practise procedures, which better support profes-
sionals and make regulation more responsive and
accountable,15 though with no clear timetable for deliv-
ery. The pandemic has further underlined the import-
ance of a regulatory framework that promotes, rather
than constrains, regulatory flexibility, not only for doc-
tors, but for all registered healthcare professionals.
Impact on BAME doctors and patients
Finally, our third concern is that discussions that
focus on immunity overlook the disproportionate
impact of the pandemic on BAME doctors and
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patients. Despite early rhetoric, COVID-19 is a dis-
ease that does discriminate.16
BAME doctors have suffered greater morbidity and
mortality, with evidence that they have been more
exposed to consequences of inadequacy of personal
protective equipment.17 Prior to the pandemic,
BAME healthcare professionals were already dispro-
portionately represented across the medicolegal land-
scape, reflected in levels of disciplinary action against
BAME staff groups,8 higher rates of referrals of doc-
tors to their regulator,18 and disproportionate repre-
sentation in criminal proceedings.3 Research
commissioned by the General Medical Council prior
to the pandemic suggests that factors that help explain
higher rates of referrals include matters such as inad-
equate induction and blame cultures, where doctors
who are ‘outsiders’ are at particular risk.18 In promot-
ing its recent guidance, the General Medical Council
should be commended for its recognition both of ‘the
disproportionate impact of disease and mortality rates
on individuals from black and minority ethnic (BME)
backgrounds’ and differences in referral patterns
between BAME and white doctors (paragraph 7).13
During the first wave of COVID-19, doctors have
worked in unfamiliar surroundings, outside of their
usual clinical areas, and we are also of the view that
there is clear potential for the factors which drive
higher referral rates to be exacerbated in this context.
However, as well as careful consideration of individual
cases, we also call for scrutiny of the wider cohort of
cases over this period to identify if there are broader
patterns or learning points that can be swiftly identi-
fied and disseminated – both to regulators and across
the health ecosystem – as we move into a second wave
of the virus.
On the other hand, it is now established that
BAME patients are also disproportionately affected
by the virus, with demonstrably greater risk of
COVID mortality.19 Therefore, it must be kept in
mind that any measures to restrict access to redress,
be this civil or regulatory, may also disproportion-
ately impact upon these groups of patients.
Furthermore, COVID-19 has highlighted the need
to conduct health research in a way that serves and
represents the whole of our community.20 If we are to
properly monitor and understand the medicolegal
implications of the pandemic, for doctors and for
patients, we believe these commitments apply equally
to data collection and research in this area. The
General Medical Council has already made decisive
moves towards making the data it collects accessible,
including in relation to fitness to practise procedures.
We call for further progress to enhance data collec-
tion on incidents and ethnicity across the health and
regulatory landscape, relating both to patients and to
healthcare professionals. The issues we have dis-
cussed in this paper are both persistent and multi-
faceted. If they are to be effectively addressed, this
information will require careful quantitative and
qualitative scrutiny as part of a coherent and collab-
orative research agenda. The General Medical
Council’s BAME Doctors’ Forum is well placed to
coordinate and inform the further work that is
needed to progress this.
Moving forward
COVID-19 is a disease which has not only posed
unprecedented challenges in its scale, it has also high-
lighted and exacerbated pre-existing issues in the
medicolegal sphere. While the focus in this domain
has so far been on protecting doctors, through
immunity legislation, our analysis indicates that
meaningful action in this area, which promotes a
just culture in healthcare, demands engagement with
a more diverse range of interests. Thus far, the med-
icolegal issues we have raised have been touched on at
a meeting convened by the all-party parliamentary
group (APPG), dedicated to ensuring that lessons
are learned from the UK’s handling of COVID-19.
Public Health England’s review into the impact of
COVID-19 on ethnic minorities alludes to action
being required to change workplace environments,21
but does not specifically address the potential medi-
colegal consequences for doctors or patients that we
have identified. Leaders have indicated that this
report has failed ethnic minorities and we now con-
sider that an independent Public Inquiry,22 with a
series of expert panels addressing specific issues,
must be convened to address these cross-cutting con-
cerns in the context of COVID-19. However, we also
call for more comprehensive action to address the
persistent issues revealed by the lens of COVID-19,
including embedding a restorative approach in
healthcare, ensuring that regulatory flexibility is sup-
ported by a coherent legislative framework and gath-
ering comprehensive data to facilitate research and
drive change (Figure 1).
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